Reata Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Reata Pharmaceuticals's estimated annual revenue is currently $53.6M per year.
- Reata Pharmaceuticals received $125.0M in venture funding in June 2018.
- Reata Pharmaceuticals's estimated revenue per employee is $128,511
- Reata Pharmaceuticals's total funding is $1.4B.
Employee Data
- Reata Pharmaceuticals has 417 Employees.
- Reata Pharmaceuticals grew their employee count by 44% last year.
Reata Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Assoc. VP, Product Development | Reveal Email/Phone |
2 | Associate VP, Bioinformatics | Reveal Email/Phone |
3 | Associate VP Pharmacovigilance | Reveal Email/Phone |
4 | Associate VP, Clinical development | Reveal Email/Phone |
5 | Associate VP, Medical Affairs EMEA | Reveal Email/Phone |
6 | Associate VP, Global Regulatory Affairs - Head RA Development Strategy & RA EMEA | Reveal Email/Phone |
7 | General Counsel | Reveal Email/Phone |
8 | AVP, Chemical and Drug Product Development | Reveal Email/Phone |
9 | VP, Scientific Strategy & Communications | Reveal Email/Phone |
10 | AVP, Discovery Chemistry | Reveal Email/Phone |
Reata Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $26.7M | 133 | 20% | N/A | N/A |
#2 | $13.5M | 67 | 6% | N/A | N/A |
#3 | $16.1M | 80 | -2% | N/A | N/A |
#4 | $62.5M | 0 | N/A | N/A | N/A |
#5 | $10.1M | 50 | 6% | N/A | N/A |
#6 | $119.4M | 594 | 27% | N/A | N/A |
#7 | $22.9M | 114 | 8% | N/A | N/A |
#8 | $92.9M | 462 | 8% | N/A | N/A |
#9 | $11.3M | 56 | -8% | N/A | N/A |
#10 | $7M | 35 | 6% | N/A | N/A |
What Is Reata Pharmaceuticals?
Reata Pharmaceuticals, Inc. (Nasdaq:RETA) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata's two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
$1.4B
Total Funding
417
Number of Employees
$53.6M
Revenue (est)
44%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Reata Pharmaceuticals News
Reata Pharmaceuticals, Inc. (NASDAQ:RETA Get Rating) has earned an average rating of Buy from the eight research firms that are covering...
Reata Pharmaceuticals (NASDAQ:RETA) stock didn't blink an eye after the FDA stuck it with a CRL because whatever damage was to be done had...
Reata Pharmaceuticals (RETA -31.4%) are struggling today, likely as a result of U.S. FDA briefing documents on Amylyx Pharma's (AMLX -55.3%)...
REATA PHARMACEUTICALS, INC. ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES AN UPDATE ON CLINICAL DEVELOPMENT PROGRAMS ADVISORY COMMITTEE MEETING for BARDOXOLONE FOR PATIENTS WITH CKD CAUSED BY ALPORT SYNDROME scheduled FOR DECEMBER 8, 2021 SUBMITTED MAA TO THE EMA FOR BARDOXOLONE ...
PLANO, Texas - Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ('Reata,' the 'Company,' or 'we'), a clinical-stage biopharmaceutical company, announced that it received a communication from the Division of Neurology Products 1 ('Division') of the U.S. Food and Drug Administration ('FDA') stating that ...
Other Companies in Irving
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $110.3M | 420 | -6% | N/A |
#2 | $171M | 421 | -4% | N/A |
#3 | $117.2M | 426 | N/A | N/A |
#4 | $151.3M | 433 | 5% | N/A |
#5 | $146.8M | 435 | 4% | N/A |
Reata Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2003-09-17 | $5.2M | Lead Investor: Ojai | Article | |
| 2004-11-12 | $12.0M | Lead Investor: Multi | Article | |
| 2006-08-07 | $22.6M | Undisclosed | Cardinal Investment Company | Article |
| 2007-07-09 | $25.0M | Undisclosed | Article | |
| 2009-03-27 | $32.0M | Undisclosed | Article | |
| 2010-07-13 | $78.0M | Undisclosed | CPMG Inc, Novo A/S | Article |
| 2016-12-07 | $Undisclosed | Undisclosed | Citigroup | Article |
| 2017-04-04 | $35.0M | Undisclosed | Oxford Finance LLC | Article |
| 2017-07-28 | $115.9M | Undisclosed | Multiple | Article |
| 2018-06-15 | $125.0M | Undisclosed | Oxford Finance LLC | Article |